Literature DB >> 12106588

Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats.

Mary A Katofiasc1, Jeffrey Nissen, James E Audia, Karl B Thor.   

Abstract

Previous studies showed that the dual serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake inhibitor, duloxetine, increases bladder capacity and urethral sphincter electromyographic (EMG) activity in a cat model of acetic acid-induced bladder irritation. The present study aimed to determine the relative importance of 5-HT versus NE reuptake inhibition for mediating these effects by examining drugs that are selective for either the 5-HT or NE system or both. Similar to duloxetine, venlafaxine (0.1 to 10 mg/kg), also a dual serotonin and norepinephrine reuptake inhibitor, produced marked increases in bladder capacity and EMG activity that were reversed by methiothepin (0.3 mg/kg). S-norfluoxetine (0.01 to 10 mg/kg), a serotonin selective reuptake inhibitor, produced small but significant increases in bladder capacity and EMG activity at doses of 3 and 10 mg/kg. Thionisoxetine (0.01 to 3.0 mg/kg), a NE selective reuptake inhibitor, produced no effects on bladder capacity or sphincter EMG activity. Surprisingly, co-administration of thionisoxetine and s-norfluoxetine up to doses of 1 mg/kg of each compound produced no effect on lower urinary tract function. These doses were the maximum that could be administered in combination due to drug-induced emergence of skeletal muscle activity in chloralose-anesthetized animals. These results indicate that there are unexplained pharmacological differences between the effects of single compounds that exhibit dual NE and 5-HT reuptake inhibition and a combination of compounds that exhibit selective NE and 5-HT reuptake inhibition on lower urinary tract function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12106588     DOI: 10.1016/s0024-3205(02)01848-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  27 in total

Review 1.  Innovations in pharmacotherapy for stress urinary incontinence.

Authors:  Tracy W Cannon; Naoki Yoshimura; Michael B Chancellor
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-20

Review 2.  CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.

Authors:  Karl-Erik Andersson; Rikard Pehrson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Pharmacotherapy for stress urinary incontinence.

Authors:  Tracy W Cannon; Michael B Chancellor
Journal:  Rev Urol       Date:  2003

4.  Neurophysiology of lower urinary tract function and dysfunction.

Authors:  Naoki Yoshimura; Michael B Chancellor
Journal:  Rev Urol       Date:  2003

5.  Properties of urethral rhabdosphincter motoneurons and their regulation by noradrenaline.

Authors:  Koji Yashiro; Karl B Thor; Edward C Burgard
Journal:  J Physiol       Date:  2010-10-25       Impact factor: 5.182

Review 6.  The role of central 5-hydroxytryptamine (5-HT, serotonin) receptors in the control of micturition.

Authors:  Andrew G Ramage
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 7.  Pharmacological treatment of pure stress urinary incontinence: a narrative review.

Authors:  Mariam A Malallah; Tariq F Al-Shaiji
Journal:  Int Urogynecol J       Date:  2015-01-29       Impact factor: 2.894

Review 8.  Coadministration of low-dose serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine with α 2-adrenoceptor blockers to treat both female and male mild-to-moderate stress urinary incontinence (SUI).

Authors:  C Alberti
Journal:  G Chir       Date:  2013 Jul-Aug

9.  Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence.

Authors:  Lars Viktrup; Beth A. Pangallo; Michael J. Detke; Norman R. Zinner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 10.  Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.

Authors:  Wolfgang Jost; Parvaneh Marsalek
Journal:  Clin Auton Res       Date:  2004-08       Impact factor: 4.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.